| Literature DB >> 21197090 |
Edyta Machura1, Bogdan Mazur, Malgorzata Rusek-Zychma, Malgorzata Barć-Czarnecka.
Abstract
There are conflicting studies on T cell cytokine production in childhood asthma. In this study intracellular cytokine expression of IL-2, IL-4, IL-10, IL-13, IFN-γ, and TNF-α in CD4(+) and CD8(+) T cells in children with atopic asthma were measured by flow cytometry. Results. A significant increase in the percentage of CD4(+) and CD8(+) T cells producing IL-4 and IL-13 and decrease in the percentage of CD4(+) producing IFN-γ in asthmatic children was found. The percentage of CD4(+)/IL-13(+) was significantly higher in severe asthma than in children with intermittent disease symptoms. Severity of asthma was associated with increased both serum IgE and frequencies of CD4(+)/IL-13(+) T cells, as well as duration of disease. Moreover, a decrease in FEV(1), FEV(1)/FVC was observed in relation to the severity of asthma. Changes in cytokine profile in CD8(+) subpopulation didn't depend on the severity of the disease. Conclusions. Increased production of IL-4 and IL-13 in both CD4(+) and CD8(+) T cells accompanied by decreased IFN-γ expression in CD4(+) T cells may be evidence that both lymphocyte subpopulations are implicated in the pathogenesis of asthma. Relationship of CD4(+)/IL-13(+) T cells with disease activity suggests that this lymphocyte subset may have a prominent role in childhood asthma.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21197090 PMCID: PMC3004408 DOI: 10.1155/2010/606139
Source DB: PubMed Journal: Clin Dev Immunol ISSN: 1740-2522
Figure 1Flow cytometric expression of CD69 (activation marker) on CD3+ T cells before (B) and after polyclonal stimulation (S) of one patient with mild asthma (male, age 9.8 yrs).
Demographic and clinical characteristics of patients with asthma and healthy children.
| Asthma | Healthy controls | |
|---|---|---|
|
| 40 | 18 |
| Age, years, mean ± SE | 9.02 ± 0.35 | 9.28 ± 0.75 |
| Sex, | M: 27; F: 13 | M: 10; F: 8 |
| Duration of asthma, years, mean ± SE | 5.46 ± 0.54 | |
| Serum total IgE, IU/ml, mean ± SE | 312.95 ± 154.00* | 28.20 ± 2.23 |
| Eosinophils, % ( | 7.2 ± 0.8 (260.4 ± 10.4)** | 2.2 ± 0.2 (137.3 ± 6.2) |
| Positive skin prick test, | 40 (100) | 0 |
|
| 37 (92.5) | |
|
| 38 (95) | |
| Grass pollens | 21 (53) | |
| Tree pollens | 12 (30) | |
| Weed pollens | 15 (38) | |
| Moulds | 10 (25) | |
| Feather | 4 (10) | |
| Cat | 8 (20) | |
| Dog | 2 (5) | |
| Total SPT wheal size, mm, mean ± SE | 21.9 ± 5.6 | |
| Current inhaled steroid use, | 30 (75) | |
| Lung function assessed, | 35 (87.5%) | 15 (83.3%) |
| FEV1% predicted | 84.3 ± 2.06# | 96.4 ± 2.047 |
| FVC% predicted | 83.3 ± 1.95# | 91.71 ± 1.41 |
| FEV1% FVC | 87.47 ± 1.63# | 91.97 ± 1.60 |
| MEF25% predicted | 85.85 ± 4.40# | 95.85 ± 4.50 |
All P-values from Mann-Whitney U-test
*P < .01
**P < .001
# P < .00001.
Percentage of CD4+ and CD8+ T cells spontaneously producing IL-2, IL-4, IL-10, IL-13, IFN-γ, and TNF-α.
| CD4+/IL-2+ | CD4+/IL-4+ | CD4+/IL-10+ | CD4+/ IL-13+ | CD4+/IFN- | CD4+/TNF- | ||
|---|---|---|---|---|---|---|---|
| Asthma | 2.75 ± 0.17 | 3.45 ± 0.24 | 3.78 ± 0.26 | 3.78 ± 0.2 | 3.0 ± 0.18 | 2.92 ± 0.15 | |
| Controls | 3.11 ± 0.31 | 2.83 ± 0.23 | 4.58 ± 0.71 | 3.33 ± 0.22 | 2.5 ± 0.26 | 3.0 ± 0.35 | |
|
| |||||||
| CD8+/IL-2+ | CD8+/IL-4+ | CD8+/IL-10+ | CD8+/IL-13+ | CD8+/IFN- | CD8+/TNF- | ||
|
| |||||||
| Asthma | 3.4 ± 0.21 | 3.45 ± 0.19* | 3.73 ± 0.31 | 4.4 ± 0.34 | 3.1 ± 0.19 | 3.53 ± 0.26 | |
| Controls | 3.58 ± 0.36 | 2.75 ± 0.13 | 4.0 ± 0.48 | 3.42 ± 0.19 | 3.08 ± 0.4 | 3.0 ± 0.28 | |
P-values from Mann-Whitney U-test
*P < .05
Data as shown as mean ± SE.
Percentage of CD4+ T cells and CD8+ T cells producing IL-2, IL-4, IL-10, IL-13, IFN-γ, and TNF-α after in vitro activation with phorbol 12-myristate-13-acetate and ionomycin.
| CD4+/IL-2+ | CD4+/IL-4+ | CD4+/IL-10+ | CD4+/IL-13+ | CD4+/IFN- | CD4+/TNF- | |
|---|---|---|---|---|---|---|
| Asthma | 7.78 ± 0.41 | 9.10 ± 0.34* | 8.73 ± 0.55 | 13.1 ± 0.39* | 7.83 ± 0.43** | 7.73 ± 0.36 |
| Controls | 9.11 ± 0.56 | 6.17 ± 0.39 | 9.25 ± 0.69 | 7.83 ± 0.49 | 11.67 ± 0.58 | 7.22 ± 0.42 |
|
| ||||||
| CD8+/IL-2+ | CD8+/IL-4+ | CD8+/IL-10+ | CD8+/IL-13+ | CD8+/IFN- | CD8+/TNF- | |
|
| ||||||
| Asthma | 8.08 ± 0.47 | 8.80 ± 0.28$ | 8.9 ± 0.5 | 13.00 ± 0.38* | 7.65 ± 0.48 | 7.75 ± 0.49 |
| Controls | 8.08 ± 0.47 | 6.08 ± 0.40 | 8.67 ± 0.63 | 7.58 ± 0.53 | 8.50 ± 0.38 | 6.83 ± 0.44 |
P-values from Mann-Whitney U-test
*P < .00001,**P < .0001, $ P < .00003
Data as shown as mean ± SE.
Figure 2(a) Flow cytometry of the cytokine production values of IL-2, IL-4, IL-10, IL-13, INF-γ, and TNF-α in CD4+ and CD8+ T subpopulations. Example of one patient with mild asthma and one control. (b) Plots of CD4+ and CD8+ T cells producing various cytokines before and after polyclonal stimulation of one patient with mild asthma (male, age 9.8 yrs) and one control (male, age-9.5 yrs). B-baseline, spontaneous cytokine staining without stimulation (in the presence of monensin alone), S-cytokine staining with stimulation (unseparated whole blood from asthma patients and healthy controls was stimulated for 4 h with PMA and ionomycin, and production of IL-2, IL-4, IL-10, IL-13, INF-γ, and TNF-α of CD4+ and CD8 T+cells was determined at the single cell levels by intracellular cytokine staining and flow cytometry as described in Section 2).
Percentage of CD4+ T cells and CD8+ T cells producing IL-2, IL-4, IL-10, IL-13, INF-γ, and TNF-α before and after in vitro activation with phorbol 12-myristate-13-acetate and ionomycin in the four groups of asthmatics (1-intermittent, 2-mild persistent, 3-moderate persistent, and 4-severe persistent asthma). In parenthesis, the frequencies of spontaneous cytokine staining (in the presence of monensin alone) are presented.
| Subgroups of asthma patients | ||||
|---|---|---|---|---|
| persistent asthma | ||||
| 1-intermittent | 2-mild | 3-moderate | 4-severe | |
| CD4+/IL-2+ | 7.5 ± 0.9 | 7.5 ± 0.6 | 9.1 ± 0.6 | 6.9 ± 0.5 |
| CD4+/IL-4+ | 9.1 ± 1.1 | 9.1 ± 0.4 | 9.6 ± 0.4 | 7.0 ± 0.41 |
| CD4+/IL-10+ | 7.1 ± 0.9 | 8.9 ± 0.9 | 8.5 ± 0.8 | 11.2 ± 0.2 |
| CD4+/IL-13+ | 11.5 ± 0.9 | 13.0 ± 0.7 | 13.3 ± 0.5 | 15.2 ± 0.2* |
| CD4+/IFN- | 6.8 ± 1.3 | 7.9 ± 0.7 | 7.0 ± 0.5 | 7.2 ± 0.2 |
| CD4+/TNF- | 8.0 ± 0.9 | 8.5 ± 0.5 | 6.5 ± 0.6 | 8.0 ± 0.4 |
| CD8+/IL-2+ | 7.5 ± 1.0 | 8.5 ± 0.8 | 7.3 ± 0.7 | 9.2 ± 0.2 |
| CD8+/IL-4+ | 8.2 ± 0.9 | 8.6 ± 0.4 | 9.3 ± 0.4 | 8.2 ± 0.2 |
| CD8+/IL-10+ | 7.5 ± 0.8 | 9.7 ± 1.0 | 8.2 ± 0.6 | 10.0 ± 0.0 |
| CD8+/IL-13+ | 12.8 ± 0.9 | 13.4 ± 0.7 | 12.2 ± 0.5 | 14.0 ± 0.5 |
| CD8+/IFN- | 7.14 ± 1.0 | 8.6 ± 0.91 | 7.1 ± 0.6 | 6.0 ± 0.0 |
| CD8+/TNF- | 7.57 ± 0.87 | 9.1 ± 0.9#
| 6.3 ± 0.6 | 7.2 ± 0.2 |
*P < .04 severe persistent asthma versus intermittent asthma.
**P < .05 severe persistent asthma versus moderate persistent asthma.
P-values from Mann-Whitney U-test.
Data as shown as mean ± SE.
Figure 3Scatterplot showing relationship between disease duration, total serum IgE, cytokine production, lung function indices, and the severity of asthma (degree of disease: 1-intermittent, 2-mild persistent, 3-moderate persistent, and 4-severe persistent asthma). Correlations were calculated using the Spearman test. (a) Duration of disease correlated highly significantly with severity of asthma (r = 0.56; P < .00003). (b) Positive correlation between total serum IgE and severity of asthma was revealed (r = 0.4; P < .001). (c) A highly negative correlation between severity of asthma and FEV1 was identified (r = −0.72; P < .000001). (d) There was a weak positive correlation between severity of asthma and the percentage of CD4+/IL10+
Figure 4Scatterplot showing relationship between asthma duration and cytokine profile of peripheral blood T cells in asthmatic patients. (a) A good positive correlation was identified between percentages of CD4+/IL-10+ following stimulation and duration of asthma (r = 0.44, P < .004). (b) A good positive correlation was identified between percentages of CD4+/IL-13+ following stimulation and duration of asthma (r = 0.4, P < .01). Correlations were calculated using the Spearman test.